Cagrilintide (5 mg Vial) Dosage Protocol
Cagrilintide (5 mg Vial) Dosage Protocol
Quickstart Highlights
Cagrilintide is a long-acting, acylated analog of the pancreatic hormone amylin that is formulated for once-weekly subcutaneous administration. It acts on central amylin receptors to enhance satiety, delay gastric emptying, and decrease overall food intake. In phase 2 and phase 3 clinical trials, cagrilintide demonstrated dose-dependent weight reduction, with adverse effects that were primarily gastrointestinal in nature.
- Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
- Typical daily range: 0.6–4.5 mg once weekly (gradual titration over 4–6 weeks)..
- Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 0.0167 mg (16.7 mcg) on a U‑100 insulin syringe.
- Storage: Lyophilized: store frozen at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 30 days.
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~ 1.67 mg/mL)
| Week/Phase | Weekly Dose (mg) | Units (per injection) | Volume (mL) |
|---|---|---|---|
| Weeks 1–2 | 0.6 mg | 36 units | 0.36 mL |
| Weeks 3–4 | 1.2 mg | 72 units | 0.72 mL |
| Weeks 5–6 | 2.4 mg | 144 units | 1.44 mL |
| Weeks 7–16 (Maintenance) | 4.5 mg | 270 units | 2.70 mL |
Note: Doses above 1.0 mL (100 units) require a 3 mL syringe with an appropriate subcutaneous needle (e.g., 25–27G, ½–⅝ inch) rather than a standard U‑100 insulin syringe. For lower starting doses (≤72 units), a U‑100 insulin syringe provides excellent accuracy.
Reconstitution Steps
Draw 3.0 mL of bacteriostatic water using a sterile syringe.
Slowly inject the solution down the inside wall of the vial, avoiding foaming or vigorous agitation.
Gently swirl or roll the vial until the contents are fully dissolved (do not shake).
Clearly label the vial with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Use within 30 days after reconstitution; discard if the solution becomes cloudy or if particulate matter is observed.
Supplies Needed
Plan based on an 8–16 week weekly protocol with gradual titration.
- Peptide Vials (Cagrilintide, 5 mg each):
- 8 weeks ≈ 4 vials (17.4 mg total)
- 12 weeks ≈ 8 vials (35.4 mg total)
- 16 weeks ≈ 11 vials (53.4 mg total)
- Syringes:
- Weeks 1–4 (doses ≤72 units): U‑100 insulin syringes work well
- Weeks 5+ (doses >100 units): 3 mL syringes with 25–27G subcutaneous needles
- Per week: 1 syringe
- 8 weeks: 8 syringes
- 12 weeks: 12 syringes
- 16 weeks: 16 syringes
- Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 12 weeks (8 vials): 24 mL → 3 × 10 mL bottles
- 16 weeks (11 vials): 33 mL → 4 × 10 mL bottles
- Alcohol Swabs: One for the vial stopper + one for the injection site each week.
- Per week: 2 swabs
- 8 weeks: 16 swabs
- 12 weeks: 24 swabs
- 16 weeks: 32 swabs → recommend 1 × 100‑count box
Protocol Overview
Concise outline of the once-weekly regimen.
- Goal: Support satiety, decrease food intake, and encourage long-term weight management.
- Schedule: Weekly subcutaneous injections for 12–16 weeks (or longer if appropriate).
- Dose Range: 0.6–4.5 mg per week with gradual titration every 2 weeks.
- Reconstitution: 3.0 mL per 5 mg vial (≈1.67 mg/mL) to allow practical volume measurements.
- Storage: Store lyophilized product frozen; refrigerate after reconstitution; avoid repeated freeze–thaw cycles.
Dosing Protocol
Suggested weekly titration approach informed by clinical trial designs.
- Start: 0.6 mg weekly for the initial 2 weeks to evaluate tolerability.
- Escalate: Increase the dose every 2 weeks (0.6 → 1.2 → 2.4 → 4.5 mg) as tolerated.
- Target: Reach 4.5 mg weekly by Weeks 7–8 and maintain at this dose.
- Frequency: Administer once weekly (subcutaneous) on the same day each week.
- Timing: Any consistent time; rotate injection sites.
Storage Instructions
Proper storage helps maintain peptide integrity and potency.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize exposure to moisture.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days and avoid freeze–thaw cycles.
Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and tolerability.
- Use a new sterile syringe for each injection; dispose of used syringes in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) weekly to help reduce local irritation.
- Gradual dose escalation helps minimize gastrointestinal side effects such as nausea.
- Record weekly dose, injection site, and any adverse effects to maintain consistency.
- For maintenance doses requiring more than 1.0 mL, ensure availability of appropriately sized syringes (3 mL).
How it works
Cagrilintide is a long-acting, acylated analogue of amylin, a hormone co-released with insulin from pancreatic beta cells. Endogenous amylin promotes satiety, delays gastric emptying, and suppresses postprandial glucagon secretion. Through activation of central amylin receptors—particularly within the area postrema and hindbrain—cagrilintide decreases appetite and overall energy intake. Lipid acylation extends its half-life to approximately 160–195 hours, allowing for once-weekly administration.
Potential Benefits & Side Effects
Observations from phase 2 and phase 3 clinical trials.
- Weight reduction: In the phase 2 study, cagrilintide 4.5 mg administered weekly resulted in approximately 10.8% body-weight reduction over 26 weeks compared with 3.0% in the placebo group.
- Combination therapy: When used alongside semaglutide 2.4 mg (CagriSema), phase 3 REDEFINE trials demonstrated roughly 20% weight loss at 68 weeks, surpassing outcomes achieved with either treatment alone.
- Dose‑dependent efficacy: Higher dose ranges (2.4–4.5 mg) are associated with greater weight loss compared with lower doses (0.3–1.2 mg).
- Side effects: Predominantly gastrointestinal, including nausea, vomiting, diarrhea, and constipation; these effects are typically mild-to-moderate and temporary. Gradual dose escalation reduces incidence and severity.
- Injection‑site reactions: Infrequent reports of mild redness or irritation at subcutaneous injection sites.
Lifestyle Factors
Complementary strategies for optimal outcomes.
- Pair with a balanced, protein-focused diet aligned with individual energy requirements.
- Combine resistance training and aerobic exercise to support metabolic health and maintain lean mass.
- Prioritize sufficient sleep (7–9 hours) and effective stress management to aid recovery and adherence.
- Monitor hydration status and electrolyte intake, particularly if gastrointestinal side effects occur
Injection Technique
General subcutaneous guidance based on clinical best-practice resources.
- Clean the vial stopper and skin with alcohol; allow to air dry completely.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Hold for 5–10 seconds before withdrawing the needle to ensure complete delivery.
- Rotate sites systematically (abdomen, thighs, upper arms) each week to avoid lipohypertroph.
Recommended Source
We recommend Ion Peptide for high-purity Cagrilintide (5 mg).
Why Ion Peptide?
- High-purity, third-party-tested batches supported by detailed COAs.
- Consistent, ISO-aligned handling practices and comprehensive documentation.
- Dependable fulfillment processes designed to preserve cold-chain integrity.
Important Note
This content is for educational purposes only and is not medical advice.